title: High doses of deferiprone may be associated with cerebellar syndrome.
authors.affiliation: Bretonneau Hospital, CHRU of Tours, Regional Centre of Pharmacovigilance, Department of Pharmacology, 37044 Tours Cedex 9, France. f.beau-salinas@chu-tours.fr
authors.forename: F
authors.initials: F
authors.lastname: Beau-Salinas
authors.forename: M A
authors.initials: MA
authors.lastname: Guitteny
authors.forename: J
authors.initials: J
authors.lastname: Donadieu
authors.forename: A P
authors.initials: AP
authors.lastname: Jonville-Bera
authors.forename: E
authors.initials: E
authors.lastname: Autret-Leca
mesh_terms: D002526:Cerebellar Diseases / Q000139:chemically induced*; D002648:Child; D000077543:Deferiprone; D005260:Female; D006801:Humans; D007502:Iron Chelating Agents / Q000008:administration & dosage / Q000009:adverse effects*; D019190:Iron Overload / Q000188:drug therapy*; D008297:Male; D011728:Pyridones / Q000008:administration & dosage / Q000009:adverse effects*; D017086:beta-Thalassemia / Q000188:drug therapy
chemical_list: D007502:Iron Chelating Agents; D011728:Pyridones; D000077543:Deferiprone